{"id":45876,"date":"2022-07-06T19:02:00","date_gmt":"2022-07-06T17:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/"},"modified":"2022-07-06T19:02:00","modified_gmt":"2022-07-06T17:02:00","slug":"calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/","title":{"rendered":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones"},"content":{"rendered":"
\n

\nInvestment Round will Fund Further Product Development <\/i>and Expansion of Calyxo\u2019s Team<\/i>\n<\/p>\n

PLEASANTON, Calif.–(BUSINESS WIRE)–#calyxo<\/a>—Calyxo, Inc.<\/a>, a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.\n<\/p>\n

\nCalyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently.\n<\/p>\n

\n\u201cWe are excited to be moving into the next step of our evolution,\u201d said Calyxo President & CEO, Joe Catanese. \u201cKidney stone disease is a painful problem for patients, and it consumes vast amounts of healthcare resources each year. We believe our solutions will better meet the needs of kidney stone patients and transform the care of this condition. We look forward to applying this latest financing round toward further product development and the expansion of our team.\u201d\n<\/p>\n

\nCatanese previously co-founded NeoTract, which developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. NeoTract was successfully acquired by Teleflex in 2017 in a transaction valued at over $1 billion. For Calyxo, Catanese has assembled a team and board which includes many of NeoTract\u2019s founding team and key players.\n<\/p>\n

\n\u201cWe are proud to invest in Calyxo and its groundbreaking kidney stone treatment technology,\u201d said Ryan Drant, Founder and Managing Partner of Questa Capital<\/a> and Calyxo board member. \u201cThe company\u2019s leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs. We look forward to supporting Calyxo through forthcoming development and commercialization milestones, and we are excited to see the team expand.\u201d\n<\/p>\n

\n\u201cCalyxo has an opportunity to alter the kidney stone treatment category and deliver a new generation of devices that can reliably improve care for millions of people afflicted by kidney stones,\u201d said Luke D\u00fcster, Chief Investment Officer of CRG<\/a>. \u201cWe are proud to support this team as it accomplishes its mission to provide a genuine solution for a long-standing medical problem.\u201d\n<\/p>\n

\nNewly released results of a nationwide study published in the Journal of Urology indicate that more than five million Americans will pass a kidney stone in 2022, a number that continues with an upward trajectory. Kidney stone disease is a painful condition that brings with it staggering healthcare costs (estimated by Current Urology Reports to reach $4.1 billion in yearly direct treatment costs by 2030). Existing kidney stone treatments do not reliably remove all the stone pieces. According to clinical studies published in Urology and the Journal of Urology, residual fragments left behind are associated with a 20%-44% rate of problems including pain, infection, emergency department visits, hospitalization and need for retreatment, demonstrating the compelling need for innovation in this space.\n<\/p>\n

\n\u201cCVAC\u201d is a registered trademark of Calyxo, Inc.<\/i>\n<\/p>\n

\nAbout Calyxo, Inc.<\/span><\/b>\n<\/p>\n

\nCalyxo, Inc. is an innovation-driven <\/i>medical device company <\/i>focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com<\/a>.<\/i>\n<\/p>\n

\nAbout Questa Capital<\/span><\/b>\n<\/p>\n

\nQuesta Capital is a venture growth equity firm focusing on investments in expansion-stage healthcare companies. Questa seeks out disruptive, technology-enabled business models that help improve patient lives, streamline market inefficiencies, and provide better quality care. The firm partners with superior management teams to help build innovative market leaders in the healthcare technology, services and medical devices sectors. Questa is led by industry veterans in healthcare investment and operations who have invested in and advised more than 50 growth-stage companies. More information is available at <\/i>www.questacapital.com<\/a><\/i>.<\/i>\n<\/p>\n

\nAbout CRG<\/span><\/strong>\n<\/p>\n

\nCRG is a premier healthcare investment firm that has committed more than $3 billion of assets across three funds to date. The firm seeks to invest between $20 to $300 million in companies across the healthcare spectrum, including: medical devices, biopharmaceuticals, tools & diagnostics, services and information technology. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution. CRG maintains offices in Boulder, New York and Houston. For more information, please visit <\/i>www.crglp.com<\/a><\/i>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPaul Williams, 310-569-0023, paul@medialinecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Investment Round will Fund Further Product Development and Expansion of Calyxo\u2019s Team PLEASANTON, Calif.–(BUSINESS WIRE)–#calyxo—Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45876","6":"format-standard","7":"category-industry"},"yoast_head":"\nCalyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Investment Round will Fund Further Product Development and Expansion of Calyxo\u2019s Team PLEASANTON, Calif.–(BUSINESS WIRE)–#calyxo—Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T17:02:00+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones\",\"datePublished\":\"2022-07-06T17:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/\"},\"wordCount\":766,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/\",\"name\":\"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-06T17:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/","og_locale":"en_US","og_type":"article","og_title":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend","og_description":"Investment Round will Fund Further Product Development and Expansion of Calyxo\u2019s Team PLEASANTON, Calif.–(BUSINESS WIRE)–#calyxo—Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T17:02:00+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones","datePublished":"2022-07-06T17:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/"},"wordCount":766,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/","url":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/","name":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-06T17:02:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/calyxo-raises-32-7-million-in-series-c-financing-to-support-novel-approach-to-treating-kidney-stones\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Calyxo Raises $32.7 Million in Series C Financing to Support Novel Approach to Treating Kidney Stones"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45876"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45876\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}